Photo: Hero Images via Getty Images
Vuno inks Europe deal for cardiac AI
Vuno has signed a memorandum of understanding with Austrian imaging AI company Contextflow and German HIS provider Mesalvo to introduce its cardiac arrest prediction tool to European hospitals.
In a press statement, the South Korean medical imaging AI firm said the partnership will focus on regulatory compliance, EHR integration, and reimbursement strategies, leveraging Mesalvo’s hospital network of more than 900 sites across Europe.
The collaboration, which also aims to validate and deploy Vuno's AI solution at scale, follows its May certification under the European Union Medical Device Regulation (EU MDR) for its flagship product.
Kakao Healthcare, Sky Labs to launch AI-powered blood pressure monitoring service
Korean health tech companies Kakao Healthcare and Sky Labs have teamed up for an integrated chronic disease service.
They recently entered into an agreement to integrate Sky Labs' ring-type continuous blood pressure monitor with Kakao's AI-powered diabetes management application for a new service. This integrated service, launching in December will enable live blood pressure tracking and provide lifestyle-based guidance.
Kakao Healthcare explained that the service will expand PASTA into a comprehensive chronic disease management platform.
The collaboration builds on their memorandum of understanding in 2022 and supports Sky Labs' push into global markets, including Europe, where they are pursuing institutional partnerships and insurance coverage.
Remidio gains CE mark for offline AI detecting glaucoma, diabetic retinopathy
India-based Remidio Innovative Solutions has received the EU MDR's CE mark for its offline AI software for detecting eye diseases.
It claims that its AI solution can spot both glaucoma and diabetic retinopathy from a single retinal scan and delivers results in under 10 seconds without internet connectivity.
The regulatory approval for its offline AI, which has been validated on over 100,000 real-world images, accelerates Remidio's expansion into Europe. The company first received a CE mark for its smartphone-based AI tool that solely detects diabetic retinopathy in 2023.
